IL284302A - History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseases - Google Patents
History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseasesInfo
- Publication number
- IL284302A IL284302A IL284302A IL28430221A IL284302A IL 284302 A IL284302 A IL 284302A IL 284302 A IL284302 A IL 284302A IL 28430221 A IL28430221 A IL 28430221A IL 284302 A IL284302 A IL 284302A
- Authority
- IL
- Israel
- Prior art keywords
- chromane
- stimulators
- oxazol
- phenyl
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,429 US10807973B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| PCT/US2019/068768 WO2020140050A1 (fr) | 2018-12-28 | 2019-12-27 | Dérivés de n-(4-(oxazol-5-yl) phényl)chromane-3-carboxamide et composés apparentés en tant que stimulateurs de la production de cellules précurseurs rétiniennes pour le traitement de maladies neurorétiniennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284302A true IL284302A (en) | 2021-08-31 |
Family
ID=69191293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284302A IL284302A (en) | 2018-12-28 | 2021-06-22 | History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10807973B2 (fr) |
| EP (1) | EP3902798B1 (fr) |
| JP (1) | JP7492964B2 (fr) |
| KR (1) | KR20210110652A (fr) |
| CN (1) | CN113227086B (fr) |
| AU (1) | AU2019413682B2 (fr) |
| BR (1) | BR112021011633A2 (fr) |
| CA (1) | CA3125327A1 (fr) |
| CL (1) | CL2021001698A1 (fr) |
| EA (1) | EA202191075A1 (fr) |
| ES (1) | ES2974562T3 (fr) |
| IL (1) | IL284302A (fr) |
| MX (1) | MX2021007815A (fr) |
| PH (1) | PH12021551133A1 (fr) |
| SG (1) | SG11202105229TA (fr) |
| WO (1) | WO2020140050A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10807973B2 (en) * | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| AU2020454040A1 (en) | 2020-06-19 | 2023-02-09 | Endogena Therapeutics, Inc. | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium |
| US11541039B2 (en) | 2020-10-08 | 2023-01-03 | Endogena Therapeutics, Inc. | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216439A1 (fr) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Produits pharmaceutiques contenant des cellules souches retiniennes |
| AU753360B2 (en) * | 1998-07-31 | 2002-10-17 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| CN101903349B (zh) * | 2007-08-27 | 2014-01-08 | Abbvie德国有限责任两合公司 | 4-(4-吡啶基)-苯甲酰胺及其作为rock活性调节剂的应用 |
| JP2011506445A (ja) * | 2007-12-13 | 2011-03-03 | アムジエン・インコーポレーテツド | γ−セクレターゼ調節剤 |
| WO2009079008A1 (fr) | 2007-12-19 | 2009-06-25 | Yangbo Feng | Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2014079850A1 (fr) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Dérivés hétérocycliques substitués |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| WO2015070170A1 (fr) * | 2013-11-08 | 2015-05-14 | The Translational Genomics Research Institute | Composés d'amélioration neuro-cognitive et méthodes d'utilisation associées |
| CA2967327C (fr) | 2014-11-07 | 2020-04-28 | The Johns Hopkins University | Traitement de retinite pigmentaire avec un n-acetylcysteine amide |
| CA2986692A1 (fr) * | 2015-05-29 | 2016-12-08 | Edge Therapeutics, Inc. | Compositions et methodes pour diminuer une perte de la vision |
| US10807973B2 (en) * | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
-
2018
- 2018-12-28 US US16/235,429 patent/US10807973B2/en active Active
-
2019
- 2019-12-27 WO PCT/US2019/068768 patent/WO2020140050A1/fr unknown
- 2019-12-27 CN CN201980085766.5A patent/CN113227086B/zh active Active
- 2019-12-27 EA EA202191075A patent/EA202191075A1/ru unknown
- 2019-12-27 JP JP2021537222A patent/JP7492964B2/ja active Active
- 2019-12-27 BR BR112021011633-8A patent/BR112021011633A2/pt unknown
- 2019-12-27 AU AU2019413682A patent/AU2019413682B2/en active Active
- 2019-12-27 ES ES19842725T patent/ES2974562T3/es active Active
- 2019-12-27 EP EP19842725.4A patent/EP3902798B1/fr active Active
- 2019-12-27 KR KR1020217023910A patent/KR20210110652A/ko unknown
- 2019-12-27 US US17/418,019 patent/US20220089583A1/en active Pending
- 2019-12-27 CA CA3125327A patent/CA3125327A1/fr active Pending
- 2019-12-27 SG SG11202105229TA patent/SG11202105229TA/en unknown
- 2019-12-27 MX MX2021007815A patent/MX2021007815A/es unknown
-
2021
- 2021-05-18 PH PH12021551133A patent/PH12021551133A1/en unknown
- 2021-06-22 IL IL284302A patent/IL284302A/en unknown
- 2021-06-24 CL CL2021001698A patent/CL2021001698A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10807973B2 (en) | 2020-10-20 |
| EP3902798C0 (fr) | 2023-12-20 |
| EA202191075A1 (ru) | 2021-10-06 |
| BR112021011633A2 (pt) | 2021-09-08 |
| CA3125327A1 (fr) | 2020-07-02 |
| PH12021551133A1 (en) | 2022-02-21 |
| US20220089583A1 (en) | 2022-03-24 |
| EP3902798B1 (fr) | 2023-12-20 |
| EP3902798A1 (fr) | 2021-11-03 |
| KR20210110652A (ko) | 2021-09-08 |
| MX2021007815A (es) | 2021-10-01 |
| SG11202105229TA (en) | 2021-07-29 |
| AU2019413682A1 (en) | 2021-06-03 |
| JP2022516087A (ja) | 2022-02-24 |
| ES2974562T3 (es) | 2024-06-27 |
| CN113227086B (zh) | 2024-07-26 |
| CL2021001698A1 (es) | 2021-12-17 |
| AU2019413682B2 (en) | 2023-11-23 |
| CN113227086A (zh) | 2021-08-06 |
| JP7492964B2 (ja) | 2024-05-30 |
| WO2020140050A1 (fr) | 2020-07-02 |
| US20200207749A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284302A (en) | History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseases | |
| EP3589628A4 (fr) | Composés pharmaceutiques aryle, hétéroaryles et hétérocycliques pour le traitement de troubles médicaux | |
| WO2017035353A8 (fr) | Composés aryle, hétéroaryle, et hétérocycliques pour le traitement de troubles médicaux | |
| MX2019002439A (es) | Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades. | |
| PH12018502142A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| SG11202011018PA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| TW201612158A (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| SG11202011010YA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
| IL278178A (en) | Use of pilocarpine hydrochloride to treat eye disorder | |
| TW201613945A (en) | Compounds and compositions as kinase inhibitors | |
| MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| PH12016501651B1 (en) | Triazine compound and use thereof for medical purposes | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| MY149058A (en) | N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b | |
| SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
| EP3579851A4 (fr) | Cellules photoréceptrices pour le traitement de maladies rétiniennes | |
| IL284700A (en) | Treatment of conditions of the eyes with similar-angiopoietin 7 inhibitors | |
| PL3749308T3 (pl) | Leczenie pacjentów z klasyczną chorobą fabry’ego migalastatem | |
| PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
| MY183209A (en) | Heterocyclic compound | |
| IL287264A (en) | Compounds and methods for the treatment of ocular disorders |